A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)

被引：0
|
作者：
Halabi, Susan
Luo, Bin
Guo, Siyuan S.
Knutson, Todd
Lyman, Jacqueline
Kobilka, Anna
Beltran, Himisha
Antonarakis, Emmanuel S.
Rosenberg, Jonathan E.
Galsky, Matt D.
Ryan, Charles J.
Kelly, William Kevin
Small, Eric J.
Morris, Michael J.
Dehm, Scott M.
Armstrong, Andrew J.
机构：
[1] Duke Univ, Duke Canc Inst Ctr Prostate & Urol Canc, Dept Biostat & Bioinformat, Sch Med, Durham, NC USA
[2] Duke Univ, Durham, NC USA
[3] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[4] Univ Minnesota, Minneapolis, MN USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY USA
[8] Mt Sinai Sch Med, New York, NY USA
[9] Prostate Canc Fdn, Santa Monica, CA USA
[10] Thomas Jefferson Univ, Dept Med Oncol & Urol, Sidney Kimmel Med Coll, Philadelphia, PA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[12] Mem Sloan Kettering Canc Ctr, New York, NY USA
[13] Duke Univ, Med Ctr, Canc Inst Ctr Prostate & Urol Canc, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5007
引用
收藏
页数：1
相关论文
共 42 条
  • [1] Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Shaya, Justin
    Randall, James Michael
    Millard, Frederick E.
    Kurzrock, Razelle
    Parsons, J. Kellogg
    Tamayo, Pablo
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric Jay
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel Peter
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    De Bono, Johann Sebastian
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] ANALYSIS OF THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA (CTDNA) IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
    Shaya, Justin
    Randall, J. Michael
    Millard, Frederick
    Kurzrock, Razelle
    Parsons, J. Kellogg
    Tamayo, Pablo
    McKay, Rana
    JOURNAL OF UROLOGY, 2020, 203 : E1094 - E1095
  • [4] Overall survival (OS) prognostic factors in metastatic castrate-resistant prostate cancer (mCRPC) patients retreated with docetaxel (D)
    Shah, Shilpa Rashmikant
    Albany, Costantine
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone
    Ravi, Praful
    Mateo, Joaquin
    Lorente, David
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan
    Wong, Sophia
    Bianchini, Diletta
    Attard, Gerhardt
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2014, 66 (01) : 8 - 11
  • [6] A validated prognostic model for predicting overall survival in patients with metastatic chemotherapy naive castrate-resistant prostate cancer
    Halabi, S.
    Lin, C. Y.
    Kelly, W. K.
    Fizazi, K.
    Moul, J. W.
    Kaplan, E.
    Morris, M. J.
    Small, E. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S679 - S679
  • [7] External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Dutta, Sandipan
    Araujo, John C.
    Logothetis, Christopher
    Sternberg, Cora N.
    Armstrong, Andrew J.
    Carducci, Michael Anthony
    Chi, Kim N.
    De Bono, Johann S.
    Petrylak, Daniel Peter
    Fizazi, Karim
    Higano, Celestia S.
    Small, Eric Jay
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Annala, Matti
    Beja, Kevin
    Vandekerkhove, Gillian
    Zulfiqar, Muhammad
    Finch, Daygen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric Jay
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel Peter
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    De Bono, Johann Sebastian
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345